Home Featured Page 4

Featured

Latest

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

Transpersonal Connections, the Body’s Memory, and the Collaborative Nature of Consciousness

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

Backed by $15m in NIDA Funding, NYU and B.More Team Up...

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of...

Philosophy and Psychedelics: Can Metaphysics Bring Meaning to Non-Ordinary States?

The Business of Psychedelics with Joe Moore and Jaime Fiorucci

Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape...

1...345...277 Page 4 of 277

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

Transpersonal Connections, the Body’s Memory, and the Collaborative Nature of Consciousness

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

Backed by $15m in NIDA Funding, NYU and B.More Team Up...

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of...

Philosophy and Psychedelics: Can Metaphysics Bring Meaning to Non-Ordinary States?

The Business of Psychedelics with Joe Moore and Jaime Fiorucci

Final Stretch for Question 4: Controversy, Advocacy, and Celebrity Voices Shape...

EDITOR PICKS

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY